Literature DB >> 28276184

Childhood predictors of written expression in late adolescents with 22q11.2 deletion syndrome: a longitudinal study.

N Hamsho1, K M Antshel1, T L Eckert1, W R Kates2.   

Abstract

BACKGROUND: 22q11.2 deletion syndrome (22q11DS) is the second most prevalent genetic syndrome and has a characteristic academic and behavioural phenotype. The primary objective of the current study was to examine the childhood predictors of written expression achievement in adolescents with 22q11DS. Written expression is an important skill that can impact an individual's overall academic performance, potentially resulting in increased levels of stress and exacerbation of psychiatric symptoms.
METHODS: A total of 119 participants were included in this study. Sixty-nine late adolescents with 22q11DS and 50 controls (consisting of a combined sample of 23 unaffected siblings of youth with 22q11DS and 27 community controls) participated in a 6-year longitudinal research project and received neuropsychological test batteries every 3 years. The Written Expression subtest of the Wechsler Individual Achievement Test - Second Edition was the primary outcome measure in the current project.
RESULTS: Findings indicated differences in childhood predictors of adolescent written expression between participants in the 22q11DS group and participants in the control group. Whereas childhood verbal IQ scores predicted adolescent written expression for participants in the control group, childhood executive function and language skills were unique predictors of adolescent written expression in individuals with 22q11DS.
CONCLUSIONS: Childhood predictors of late adolescent written expression in 22q11DS differ in meaningful ways from predictors in the non-22q11DS population. These results offer some guidance on the underlying factors that may be useful to consider when developing written expression interventions for children with 22q11DS.
© 2017 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.

Entities:  

Keywords:  22q11.2 deletion syndrome; developmental disorder; executive functioning; written expression

Mesh:

Year:  2017        PMID: 28276184      PMCID: PMC5542409          DOI: 10.1111/jir.12370

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  28 in total

1.  The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis.

Authors:  A Miyake; N P Friedman; M J Emerson; A H Witzki; A Howerter; T D Wager
Journal:  Cogn Psychol       Date:  2000-08       Impact factor: 3.468

2.  Cognitive development in children with 22q11.2 deletion syndrome.

Authors:  Sasja N Duijff; Petra W J Klaassen; Henriette F N Swanenburg de Veye; Frits A Beemer; Gerben Sinnema; Jacob A S Vorstman
Journal:  Br J Psychiatry       Date:  2012-06       Impact factor: 9.319

3.  Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis.

Authors:  Martino Belvederi Murri; Carmine M Pariante; Paola Dazzan; Nilay Hepgul; Andrew S Papadopoulos; Patricia Zunszain; Marta Di Forti; Robin M Murray; Valeria Mondelli
Journal:  Psychoneuroendocrinology       Date:  2011-09-17       Impact factor: 4.905

4.  Learning to improve: using writing to increase critical thinking performance in general education biology.

Authors:  Ian J Quitadamo; Martha J Kurtz
Journal:  CBE Life Sci Educ       Date:  2007       Impact factor: 3.325

5.  Predicting reading comprehension academic achievement in late adolescents with velo-cardio-facial (22q11.2 deletion) syndrome (VCFS): a longitudinal study.

Authors:  K Antshel; B Hier; W Fremont; S V Faraone; W Kates
Journal:  J Intellect Disabil Res       Date:  2014-05-26

6.  Early speech and language development in children with velocardiofacial syndrome.

Authors:  N J Scherer; L L D'Antonio; J H Kalbfleisch
Journal:  Am J Med Genet       Date:  1999-12-15

7.  Autism spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome.

Authors:  Sarah E Fine; Alison Weissman; Marsha Gerdes; Jennifer Pinto-Martin; Elaine H Zackai; Donna M McDonald-McGinn; Beverly S Emanuel
Journal:  J Autism Dev Disord       Date:  2005-08

8.  ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome.

Authors:  Kevin M Antshel; Wanda Fremont; Nancy J Roizen; Robert Shprintzen; Anne Marie Higgins; Amit Dhamoon; Wendy R Kates
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-05       Impact factor: 8.829

9.  A longitudinal examination of the psychoeducational, neurocognitive, and psychiatric functioning in children with 22q11.2 deletion syndrome.

Authors:  Stephen R Hooper; Kathleen Curtiss; Kelly Schoch; Matcheri S Keshavan; Andrew Allen; Vandana Shashi
Journal:  Res Dev Disabil       Date:  2013-03-16

10.  Intellectual abilities in a large sample of children with Velo-Cardio-Facial Syndrome: an update.

Authors:  B De Smedt; K Devriendt; J-P Fryns; A Vogels; M Gewillig; A Swillen
Journal:  J Intellect Disabil Res       Date:  2007-09
View more
  3 in total

Review 1.  Pathways to understanding psychosis through rare - 22q11.2DS - and common variants.

Authors:  Raquel E Gur; David R Roalf; Aaron Alexander-Bloch; Donna M McDonald-McGinn; Ruben C Gur
Journal:  Curr Opin Genet Dev       Date:  2021-02-08       Impact factor: 5.578

2.  Abnormalities in gray matter microstructure in young adults with 22q11.2 deletion syndrome.

Authors:  Zora Kikinis; Nikos Makris; Valerie J Sydnor; Sylvain Bouix; Ofer Pasternak; Ioana L Coman; Kevin M Antshel; Wanda Fremont; Marek R Kubicki; Martha E Shenton; Wendy R Kates; Yogesh Rathi
Journal:  Neuroimage Clin       Date:  2018-11-27       Impact factor: 4.881

Review 3.  Deletion Syndrome 22q11.2: A Systematic Review.

Authors:  Jonathan Cortés-Martín; Nuria López Peñuela; Juan Carlos Sánchez-García; Maria Montiel-Troya; Lourdes Díaz-Rodríguez; Raquel Rodríguez-Blanque
Journal:  Children (Basel)       Date:  2022-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.